Fibrosis in hypertensive heart disease: Role of the renin-angiotensin- aldosterone system

Medical Clinics of North America

Volumn 88, Issue 1, 2004, Pages 83-97

  González, Arantxa ^a   López, Begoña ^a   Díez, Javier ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

APOPTOSIS; ARTERIOLE; AUTOCRINE EFFECT; CAPILLARY DENSITY; CELL GROWTH; CELL PROLIFERATION; CLINICAL FEATURE; COLLAGEN SYNTHESIS; ENDOCRINE SYSTEM; ESSENTIAL HYPERTENSION; EVIDENCE BASED MEDICINE; EXTRACELLULAR MATRIX; FIBROBLAST; HEART DISEASE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HUMAN; HYPERPLASIA; HYPERTENSION; HYPERTENSIVE HEART DISEASE; HYPERTROPHIC CARDIOMYOPATHY; MOLECULAR DYNAMICS; MUSCLE ATROPHY; NECROSIS; NONHUMAN; PARACRINE SIGNALING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SCAR FORMATION;

EID: 0742270298     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(03)00125-1     Document Type: Review

References (100)

1. Weber K.T. Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair. Semin Nephrol. 17:1997;467-491.
2. Tan L.B., Jalil J.E., Pick R., Janicki J.S., Weber K.T. Cardiac myocyte necrosis induced by angiotensin II. Circ Res. 69:1991;1185-1195.
3. Benjamin I.J., Jalil J.E., Tan L.B., Cho K., Weber K.T., Clark W.A. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res. 65:1989;657-670.
4. Ratajska A., Campbell S.E., Sun Y., Weber K.T. Angiotensin II associated cardiac myocyte necrosis: role of adrenal catecholamines. Cardiovasc Res. 28:1994;684-690.
5. Sun Y., Cleutjens J.P., Diaz-Arias A.A., Weber K.T. Cardiac angiotensin converting enzyme and myocardial fibrosis in the rat. Cardiovasc Res. 28:1994;1423-1432.
6. Jugdutt B.I., Amy R.W. Healing after myocardial infarction in the dog: changes in infarct hydroxyproline and topography. J Am Coll Cardiol. 7:1986;91-102.
7. Weber K.T., Brilla C.G. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 83:1991;1849-1865.
8. Brilla C.G., Pick R., Tan L.B., Janicki J.S., Weber K.T. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res. 67:1990;1355-1364.
9. Sun Y., Ratajska A., Zhou G., Weber K.T. Angiotensin-converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone. J Lab Clin Med. 122:1993;395-403.
10. Goldblatt H. Experimental hypertension induced by renal ischemia (Harvey Lecture). Bull N Y Acad Med. 14:1938;523-553.
11. Hall C.E., Hall O. Hypertension and hypersalimentation. I. Aldosterone hypertension. Lab Invest. 14:1965;285-294.
12. Weber K.T. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol. 13:1989;1637-1652.
13. Weber K.T. Stroma and the search for common ground. Plumbism or promiscuity? Cardiovasc Res. 29:1995;330-335.
14. Müller G.A., Schettler V., Müller C.A., Strutz F. Prevention of progression of renal fibrosis: How far are we? Kidney Int. 49:(suppl 54):1996;S75-S82.
15. Eddy A.A. Interstitial macrophages as mediators of renal fibrosis. Exp Nephrol. 3:1995;76-79.
16. Adler K.B., Low R.B., Leslie K.O., Mitchell J., Evans J.N. Biology of disease: contractile cells in normal and fibrotic lung. Lab Invest. 60:1989;473-485.
17. Dunnill M.S. Pulmonary fibrosis. Histopathology. 16:1990;321-329.
18. Friedman S.L. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis: mechanisms and treatment strategies. N Engl J Med. 328:1993;1828-1835.
19. Pérez-Tamayo R. Collagen resorption in carrageenin granulomas. I. Collagenolytic activity in in vitro explants. Lab Invest. 22:1970;137-141.
20. Kuncio G.S., Neilson E.G., Haverty T. Mechanisms of tubulointerstitial fibrosis. Kidney Int. 39:1991;550-556.
21. Strutz F., Müller G.A. On the progression of chronic renal disease. Nephron. 69:1995;371-379.
22. Weber K.T., Sun Y., Campbell S.E., Slight S.H., Ganjam V.K., Griffing G.T., et al. Chronic mineralocorticoid excess and cardiovascular remodeling. Steroids. 60:1995;125-132.
23. Beltrami C.A., Finato N., Rocco M., Feruglio G.A., Puricelli C., Cigola E., et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation. 89:1994;151-163.
24. Tanaka M., Fujiwara H., Onodera T., Wu D.J., Hamashima Y., Kawai C. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J. 55:1986;575-581.
25. Olivetti G., Melissari M., Balbi T., Quaini F., Cigola E., Sonnenblick E.H., et al. Myocyte cellular hypertrophy is responsible for ventricular remodelling in the hypertrophied heart of middle aged individuals in the absence of cardiac failure. Cardiovasc Res. 28:1994;1199-1208.
26. Rossi M.A. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens. 16:1998;1031-1041.
27. Ciulla M., Paliotti R., Hess D.B., Tjhja E., Campbell S.E., Magrini F., et al. Echocardiographic patterns of myocardial fibrosis in hypertensive patients: endomyocardial biopsy versus ultrasonic tissue characterization. J Am Soc Echocardiogr. 10:1997;657-664.
28. Schwartzkopff B., Brehm M., Mundehenke M., Strauer B.E. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension. 36:2000;220-225.
29. Brilla C.G., Funck R.C., Rupp R.H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 102:2000;1388-1393.
30. Querejeta R., Varo N., López B., Larman M., Artiñano E., Etayo J.C., et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 101:2000;1729-1735.
31. Pardo-Mindán F.J., Panizo A. Alterations in extracellular matrix of the myocardium in essential hypertension. Eur Heart J. 14:(suppl J):1993;12-14.
32. Burlew B.S., Weber K.T. Connective tissue and the heart: functional significance and regulatory mechanisms. Cardiol Clin. 18:2000;435-442.
33. Bishop J.E., Lindahl G. Regulation of cardiovascular collagen synthesis by mechanical load. Cardiovasc Res. 42:1999;27-44.
34. Amanuma S., Sekiguchi M., Ogasawara S., Honda M., Hosoda S. Biventricular endomyocardial biopsy findings in essential hypertension of graded severity. Postgrad Med J. 70:(suppl 1):1994;S67-S71.
35. Pearlman E.S., Weber K.T., Janicki J.S., Pietra G.G., Fishman A.P. Muscle fiber orientation and connective tissue content in the hypertrophied human heart. Lab Invest. 46:1982;158-164.
36. López B., Querejeta R., Varo N., González A., Larman M., Martínez Ubago J.L., et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation. 104:2001;286-291.
37. Weber K.T. Fibrosis and hypertensive heart disease. Curr Opin Cardiol. 15:2000;264-272.
38. Díez J., López B., González A., Querejeta R. Clinical aspects of hypertensive myocardial fibrosis. Curr Opin Cardiol. 16:2001;328-335.
39. Sun Y., Ramires F.J.A., Weber K.T. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res. 35:1997;138-147.
40. Jalil J.E., Janicki J.S., Pick R., Weber K.T. Coronary vascular remodeling and myocardial fibrosis in the rat with renovascular hypertension: response to captopril. Am J Hypertens. 4:1991;51-55.
41. Everett A.D., Tufro-Mcreddie A., Fisher A., Gomez R.A. Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-β1 expression. Hypertension. 23:1994;587-592.
42. Campbell J.E., Janicki J.S., Weber K.T. Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. J Mol Cell Cardiol. 27:1995;1545-1560.
43. Brilla C.G., Matsubara L.S., Weber K.T. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary aldosteronism. J Mol Cell Cardiol. 25:1993;563-575.
44. Kim S., Ohta K., Hamaguchi A., Yukimura T., Miura K., Iwao H. Angiotensin II-induced cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension. 25:1995;1252-1259.
45. Crawford D.C., Chobanian A.V., Brecher P. Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat. Circ Res. 74:1994;727-739.
46. Lee M.A., Bohm M., Paul M., Bader M., Ganten U., Ganten D. Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Am J Physiol. 270:1996;E919-E929.
47. Bishop J.E., Kiernan L.A., Montgomery H.E., Gohlke P., Mcewan J.R. Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats. Cardiovasc Res. 47:2000;57-67.
48. Pinto Y.M., Pinto-Sietsma S.J., Philipp T., Engler S., Kossmehl P., Hocher B., et al. Reduction in left ventricular messenger RNA for transforming growth factor beta (1) attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR(mRen2)27 rat. Hypertension. 36:2000;747-754.
49. Rothermund L., Kreutz R., Kossmehl P., Fredersdorf S., Shakibaei M., Schulze-Tamzil G., et al. Early onset of chondroitin sulfate and osteopontin expression in angiotensin II-dependent left ventricular hypertrophy. Am J Hypertens. 15:2002;644-652.
50. Teisman A.C., Pinto Y.M., Buikema H., Flesch M., Bohm M., Paul M., et al. Dissociation of blood pressure reduction from end-organ damage in TGR(mREN2)27 transgenic hypertensive rats. J Hypertens. 16:1998;1759-1765.
51. Brilla C.G., Janicki J.S., Weber K.T. Impaired diastolic function and coronary reserve in genetic hypertension: role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res. 69:1991;107-115.
52. Varo N., Etayo J.C., Zalba G., Beaumont J., Iraburu M.J., Montiel C., et al. Losartan inhibits the postranscriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens. 17:1999;101-114.
53. 1 blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension. 35:2000;1197-1202.
54. Sadoshima J., Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Circ Res. 73:1993;413-423.
55. Bouzegrhane F., Thibault G. Is angiotensin II a proliferative factor of cardiac fibroblasts? Cardiovasc Res. 53:2002;304-312.
56. Schnee J.M., Hsueh W.A. Angiotensin II, adhesion, and cardiac fibrosis. Cardiovasc Res. 46:2000;264-268.
57. Graf K., Neuss M., Stawowy P., Hsueh W.A., Pleck E., Law R.E. Angiotensin II and alpha(V)beta(3) integrin expression in rat neonatal cardiac fibroblasts. Hypertension. 35:2000;978-984.
58. Ashizawa N., Graf K., Do Y.S., Nunohiro T., Giachelli C.M., Meehan W.P., et al. Osteopontin is produced by rat cardiac fibroblasts and mediates AII-induced DNA synthesis and collagen gel contraction. J Clin Invest. 98:1996;2218-2227.
59. Dostal D.E., Booz G.W., Baker K.M. Angiotensin II signaling pathways in cardiac fibroblasts: conventional versus novel mechanisms in mediating cardiac growth and function. Mol Cell Biochem. 157:1996;15-21.
60. Tharaux P.L., Chatziantoniou C., Fakhouri F., Dussaule J.C. Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway. Hypertension. 36:2000;330-336.
61. Ghiggeri G.M., Oleggini R., Musante L., Garidi G., Gusmano R., Ravazzolo R. A DNA element in the α1 type III collagen promoter mediates a stimulatory response by angiotensin II. Kidney Int. 58:2000;537-548.
62. Crabos M., Roth M., Hahn A.W., Erne P. Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts: coupling to signaling systems and gene expression. J Clin Invest. 93:1994;2372-2378.
63. Villarreal F.J., Kim N.N., Ungab G.D., Printz M.P., Dillmann W.H. Identification of functional angiotensin II receptors on cardiac fibroblasts. Circulation. 88:1993;2849-2861.
64. Dostal D.E. Regulation of cardiac collagen: angiotensin and cross-talk with local growth factors. Hypertension. 37:2001;841-844.
65. Hao J., Wang B., Jones S.C., Jassal D.S., Dixon I.M. Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro. Am J Physiol. 279:2000;H3020-H3030.
66. Shindo T., Manabe I., Fukushima Y., Tobe K., Aizawa K., Miyamoto S., et al. Krüppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat Med. 8:2002;856-863.
67. Tomita H., Egahsira K., Ohara Y., Takemoto M., Koyanagi M., Katoh M., et al. Early induction of transforming growth factor-β via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension. 32:1998;273-279.
68. Gray M.O., Long C.S., Kalinyak J.E., Li H.T., Karliner J.S. Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovasc Res. 40:1998;352-363.
69. Guarda E., Katwa L.C., Myers P.R., Tyagi S.C., Weber K.T. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res. 27:1993;2130-2134.
70. Ammarguellat F., Larouche I.I., Schiffrin E.L. Myocardial fibrosis in DOCA-salt hypertensive rats: effect of endothelin (ETA) receptor antagonism. Circulation. 103:2001;319-324.
71. Yamamoto K., Masuyama T., Sakata Y., Nishikawa N., Mano T., Hori M. Prevention of diastolic heart failure by endothelin type A receptor antagonist through inhibition of ventricular structural remodeling in hypertensive heart. J Hypertens. 20:2002;753-761.
72. Leipala J.A., Takala T.E., Ruskoaho H., Myllyla R., Kainulainen H., Hassinen I.E., et al. Transmural distribution of biochemical markers of total protein and collagen synthesis, myocardial contraction speed and capillary density in the rat left ventricle in angiotensin II-induced hypertension. Acta Physiol Scand. 133:1988;325-333.
73. Ju H., Zhao S., Jassal D.S., Dixon I.M. Effect of AT1 receptor blockade on cardiac collagen remodeling after myocardial infarction. Cardiovasc Res. 35:1997;223-232.
74. Funck R.C., Wilke A., Rupp H., Brilla C.G. Regulation and role of myocardial matrix remodeling in hypertensive heart disease. Adv Exp Mol Biol. 432:1997;35-44.
75. Chua C.H., Hamdy R.C., Chua B.H. Angiotensin II induces TIMP-1 production in rat heart endothelial cells. Biochem Biophys Acta. 1311:1996;175-180.
76. Edwards D.R., Murphy G., Reynolds J.J., Whitham S.E., Docherty A.J., Angel P., et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J. 6:1987;1899-1904.
77. Chua C.C., Chua B.H., Zhao Z.Y., Krebs C., Diglio C., Perrin E. Effect of growth factors on collagen metabolism in cultured human heart fibroblasts. Connect Tissue Res. 26:1991;271-281.
78. 1) transgenic mice is associated with inhibition of interstitial collagenase. Eur J Clin Invest. 32:2002;295-303.
79. Kawano H., Do Y.S., Kawano Y., Starnes V., Barr M., Law R.E., et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation. 101:2000;1130-1137.
80. Kobayashi N., Nakano S., Mita S., Kobayashi T., Honda T., Tsubokou Y., et al. Involvement of Rho-kinase pathway for angiotensin II-induced plasminogen activator inhibitor-1 gene expression and cardiovascular remodeling in hypertensive rats. J Pharmacol Exp Ther. 301:2002;459-466.
81. Yamamoto K., Saito H. A pathological role of increased expression of plasminogen activator inhibitor-1 in human or animal disorders. Int J Hematol. 68:1998;371-385.
82. Dollery C.M., Mcewan J.R., Henney A.M. Matrix metalloproteinases and cardiovascular diseases. Circ Res. 77:1995;863-868.
83. Weber K.T., Sun Y., Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension. 23:1994;869-877.
84. Young M., Fullerton M., Dilley R., Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest. 93:1994;2578-2583.
85. Lombes M., Alfaidy N., Eugene E., Lessana A., Farman N., Bonvalet J.P. Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation. 92:1995;175-182.
86. Brilla C.G., Zhou G., Matsubara L., Weber K.T. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol. 26:1994;809-820.
87. Brilla C.G., Matsubara L.S., Weber K.T. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol. 71:1993;12A-16A.
88. Nicoletti A., Heudes D., Hinglais N., Appay M.D., Philippe M., Sassy-Prigent C., et al. Left ventricular fibrosis in renovascular hypertensive rats: effect of losartan and spironolactone. Hypertension. 26:1995;101-111.
89. Lacolley P., Safar M.E., Lucet B., Ledudal K., Labat C., Benetos A. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol. 37:2001;662-667.
90. Sun Y., Weber K.T. Ang II and aldosterone receptor binding in rat heart and kidney: response to chronic angiotensin II or aldosterone. J Lab Clin Med. 122:1993;404-411.
91. 1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension. 33:1999;981-986.
92. Takeda Y., Yoneda T., Demure M., Miyamori I., Mabuchi H. Cardiac aldosterone production in genetically hypertensive rats. Hypertension. 36:2000;495-500.
93. Yamamoto N., Yasue H., Mizuno Y., Yoshimura M., Fujii H., Nakayama M., et al. Aldosterone is produced from ventricles in patients with essential hypertension. Hypertension. 39:2002;958-962.
94. Grandi A.M., Imperiale D., Santillo R., Barlocco E., Bertolini A., Guasti L., et al. Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension. 40:2002;647-652.
95. MacFadyen R.J., Barr C.S., Struthers A.D. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res. 35:1997;30-34.
96. Zannad F., Alla F., Dousset B., Perez A., Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 102:2000;2700-2706.
97. Tsutamoto T., Wada A., Maeda K., Mabuchi N., Hayashi M., Tsutsui T., et al. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol. 36:2000;838-844.
98. Hayashi M., Tsutamoto T., Wada A., Maeda K., Mabuchi N., Tsutsui T., et al. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol. 38:2001;1375-1382.
99. Hayashi M., Tsutamoto T., Wada A., Tsutsui T., Ishii C., Ohno K., et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation. 107:2003;2559-2565.
100. Modena M.G., Aveta P., Menozzi A., Rossi R. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J. 141:2001;41-46.